Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

L.A. McKeown

March 25, 2024

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

L.A. McKeown

October 08, 2021

News Conference News VIVA 2020

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

L.A. McKeown

November 27, 2020

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

L.A. McKeown

November 09, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Daily News

CMS Lauded for Coverage Decision on Supervised Exercise Therapy for PAD

L.A. McKeown

June 08, 2017

News Conference News VEITH 2015

DCBs for Femoropoliteal Disease: What’s Now and What’s Next?

Yael L. Maxwell

November 19, 2015

Presentation TCT 2014

Impact of Disease Complexity on Technical Approach and Clinical Outcomes: Methodological Considerations for the Evaluation of DCB Safety and Efficacy

Presenter: Gary M. Ansel, Jihad A. Mustapha, Douglas E. Drachman, Peter A. Schneider

September 15, 2014

Presentation TCT 2014

TCT 269: Drug-Coated Balloon vs Standard Balloon for the PTA Treatment of Lesions in the SFA and Popliteal Artery? First Interim Results of the FREERIDE Study

Presenter: Peter A. Schneider, Gunnar Tepe, Michael H. Wholey, Schulte Karl-Ludwig, MD

September 15, 2014

Advertisement

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

FDA’s First Take on New Paclitaxel Concerns in CLI

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

CMS Lauded for Coverage Decision on Supervised Exercise Therapy for PAD

DCBs for Femoropoliteal Disease: What’s Now and What’s Next?

Impact of Disease Complexity on Technical Approach and Clinical Outcomes: Methodological Considerations for the Evaluation of DCB Safety and Efficacy

TCT 269: Drug-Coated Balloon vs Standard Balloon for the PTA Treatment of Lesions in the SFA and Popliteal Artery? First Interim Results of the FREERIDE Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content